Roche (RHHBY) & Lilly to Co-Develop Alzheimer's Detection Device
Roche Holding AG RHHBY announced a collaboration with Eli Lilly and Company LLY where the latter shall support the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). EAPP is Roche’s proprietary innovative blood test that seeks to facilitate the earlier diagnosis of Alzheimer’s Disease (AD).
In the past year, the shares of Roche have dropped 29.6% against the industry’s 1% increase.
Image Source: Zacks Investment Research
AD is a highly concerning neurodegenerative disease with a limited scope of early and accurate diagnosis. Globally, about 75% of people living with AD symptoms are without a conclusive diagnosis. Moreover, people who have received a diagnosis, have had to wait 2.8 years on average after the onset of symptoms. Under such circumstances, Roche and Lilly believe that the strain put on healthcare systems by AD can be partially relieved by making a patient’s journey to a diagnosis faster and more accessible, which will therefore enable early access to potential future therapies.
Roche’s EAPP measures phosphorylated Tau (pTau) 181 protein assay and apolipoprotein (APOE) E4 assay in human blood plasma.Elevations in pTau181 occur in the early stages of Alzheimer’s, while the presence of APOE4 constitutes the most common genetic risk factor for AD. A negative reading following the test with the EAPP signifies that the patient is unlikely to be amyloid-positive and should be investigated for other causes of cognitive decline.
We would like to remind the investors that in July 2022, the FDA granted the breakthrough device designation to Roche’s EAPP. Last December, Roche also received FDA 510(k) clearance for its Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (pTau181) assays, which identify Alzheimer's pathology in its early symptomatic stage.
Roche Holding AG Price and Consensus
Roche Holding AG price-consensus-chart | Roche Holding AG Quote
Zacks Rank and Stocks to Consider
Roche currently has a Zacks Rank #3 (Hold).
Some top-ranked stocks in the overall healthcare sector are Novo Nordisk NVO, which sports a Zacks Rank #1 (Strong Buy) and Avalo Therapeutics AVTX, carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 90 days, The Zacks Consensus estimate for Novo Nordisk’s 2023 earnings per share has risen from $4.03 to $4.43. Shares of Novo Nordisk have risen 34.6% in the past year.
NVO beat earnings estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 3.00%, on average.
In the last 90 days, Avalo’s loss estimates for the year 2023 have narrowed from $3.62 to $1.56 per share. In the past year, the shares of Avalo have plunged 74.1%.
AVTX beat earnings estimates in two of the last three reported quarters, missing the mark on one occasion, delivering an average earnings surprise of 37.83%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Roche Holding AG (RHHBY) : Free Stock Analysis Report
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
Eli Lilly and Company (LLY) : Free Stock Analysis Report
Avalo Therapeutics, Inc. (AVTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.